
Please try another search
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology. In addition, the company engages in the investment, consulting, service, and transfer of techniques activities. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Fang Wei Ding | - | - | Member of the Supervisory Board |
Xue Ling Wang | - | - | Director |
Wan-Lai Cheng | - | - | Director |
Hsueh-Lin Wang | - | - | Independent Director |
Hai I Ma | - | 2021 | Independent Director |
Chih-Hsiung Wu | - | - | Independent Director |
Zhixiong Wu | - | - | Independent Director |
Xinrong Lin | - | - | Independent Director |
De-Fu Hsieh | - | 2025 | Representative Director |
Chia-Ling Lin | - | 2024 | Representative Director |
Xie Defu | - | - | Director |
Shinn-Zong Lin | - | 2025 | Independent Director |
Su-Chi Wang | - | 2024 | Chairman of the Board |
Chih Yung Chin | 62 | - | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review